Skip to main content
Nima Mosammaparast, MD, Pathology, Saint Louis, MO, Barnes-Jewish Hospital

NimaMosammaparastMDPhD

Pathology Saint Louis, MO

Anatomic Pathology, Clinical Pathology

Professor of Pathology and Immunology, and of Oncology, Washington University in St. Louis School of Medicine; Co-Director, DNA Metabolism & Repair Program, Siteman Cancer Center

Dr. Mosammaparast is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Mosammaparast's full profile

Already have an account?

Summary

  • Dr. Nima Mosammaparast is a pathologist in Saint Louis, MO. He received his medical degree from University of Virginia School of Medicine and has been in practice 11 years. He specializes in clinical pathology.

Education & Training

  • Brigham and Women's Hospital/Harvard Medical School
    Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Research, 2009 - 2011
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Pathology-Anatomic and Clinical, 2006 - 2009
  • University of Virginia School of Medicine
    University of Virginia School of MedicineClass of 2006

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2024 - 2026
  • MO State Medical License
    MO State Medical License 2013 - 2025
  • American Board of Pathology Pathology - Clinical

Publications & Presentations

PubMed

Journal Articles

  • RNA Ligase-like Domain in Activating Signal Cointegrator 1 Complex Subunit 1 (ASCC1) Regulates ASCC Complex Function During Alkylation Damage  
    Nima Mosammaparast, MD, The Journal of Biological Chemistry

Press Mentions

  • Experimental Drug Treatment Stops a Deadly Form of Lung Cancer in Mice
    Experimental Drug Treatment Stops a Deadly Form of Lung Cancer in MiceSeptember 8th, 2022
  • Experimental Drug Treatment Stops a Deadly Form of Lung Cancer in Mice : ScienceAlert
    Experimental Drug Treatment Stops a Deadly Form of Lung Cancer in Mice : ScienceAlertSeptember 7th, 2022
  • Experimental Drug Treatment Stops a Deadly Form of Lung Cancer in Mice
    Experimental Drug Treatment Stops a Deadly Form of Lung Cancer in MiceSeptember 7th, 2022
  • Join now to see all

Grant Support

  • A signaling pathway specific for alkylation damageNIH/NCI2019–2024
  • Research Scholar AwardAmerican Cancer Society2019–2023
  • Mechanism and regulation of the DNA alkylation damage responseNIH/NCI2015–2020

Hospital Affiliations